Organogenesis (NASDAQ:ORGO) Shares Gap Down – What’s Next?

Organogenesis Holdings Inc. (NASDAQ:ORGO)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $4.43, but opened at $4.29. Organogenesis shares last traded at $3.93, with a volume of 540,727 shares.

Organogenesis Stock Down 3.6 %

The company has a current ratio of 3.09, a quick ratio of 2.42 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $511.76 million, a P/E ratio of -64.33 and a beta of 1.60. The stock has a 50 day moving average price of $2.99 and a 200 day moving average price of $2.82.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period last year, the company earned $0.02 earnings per share. On average, research analysts anticipate that Organogenesis Holdings Inc. will post -0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Organogenesis

Institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. grew its stake in shares of Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after purchasing an additional 3,005,450 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Organogenesis by 18.6% during the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock worth $8,521,000 after buying an additional 471,741 shares during the period. AQR Capital Management LLC grew its position in shares of Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after buying an additional 986,132 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Organogenesis by 19.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after buying an additional 333,123 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of Organogenesis by 1,350.3% during the second quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after acquiring an additional 88,175 shares during the last quarter. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.